Informed consent has always been an ethical and legal baseline in medicine. In non-FDA-approved stem cell therapy, it is now also a specific statutory compliance requirement, and the elements differ by state. Florida SB 1768, Utah’s amended Section 58-1-512, and Wyoming SF 48 each condition lawful practice on a written consent that contains particular elements, which means a form that satisfies general medical ethics can still violate a state statute by omitting one required line. What follows compiles the consent requirements across the three active states so a physician can build a form that holds up in each.
TLDR: Florida SB 1768 and Utah’s Section 58-1-512 (as amended by SB 275) both enumerate the same core consent elements: a statement that the therapy is not FDA-approved, the anticipated results, available alternatives, material risks, and the option to decline, with the form signed and retained in the record. Wyoming SF 48 requires written consent and a documented physician-patient relationship but does not enumerate elements the same way, so the Florida and Utah elements serve as a sensible floor pending Wyoming counsel review. A consent form that meets general ethics standards but omits a state-required element is a statutory violation regardless of intent. Banking adipose tissue does not enroll a patient in therapy and does not guarantee any future eligibility, access, or benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently holds FDA approval for the conditions discussed in this article. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
A consent form is the single most reviewable artifact in a stem cell practice. It is signed, dated, and sitting in the record, which makes it the first thing a board investigator or plaintiff’s attorney reads. Getting the elements right is not paperwork hygiene; it is the difference between a defensible file and a per-encounter statutory violation.
Why Consent Documentation Is a Compliance Issue, Not Just an Ethics Issue
The shift worth internalizing is that consent has moved from a standard of care into the statute itself. When a state law enumerates required consent elements, the consent form becomes a compliance document, and an omission is a violation of that law independent of whether the patient was actually well informed. A physician can have a thorough verbal conversation, document it in a chart note, and still be out of compliance because the statute requires specific elements in a signed writing. The elements below are drawn from each state’s enacted text and should be read against that text before a form is finalized. The federal backdrop also matters: no adipose-derived product is FDA-approved for these uses, and the FDA-status statement is the element every state requires.
Florida SB 1768 Consent Requirements
Florida’s SB 1768 requires that the written informed consent for non-FDA-approved stem cell therapy include a statement that the therapy is not approved by the FDA, the anticipated results of the therapy, the alternative therapies available to the patient, the material risks associated with the therapy, and the option of not receiving the therapy. The form must be signed by the patient and retained in the patient’s medical record.
On retention, SB 1768 does not set a therapy-specific period beyond Florida’s general medical-records rules. Florida physicians generally retain records for a defined period tied to the last patient entry, with longer retention for minors, so the consent should follow the practice’s standard records-retention policy. Confirm the exact period with Florida counsel rather than assuming a number, because the governing rule is the general records statute, not SB 1768 itself. The full Florida obligation set, including sourcing and advertising, is laid out in the FDA regulations overview for adipose tissue.
Utah Section 58-1-512 Consent Requirements
Utah’s Section 58-1-512, as amended by SB 275, requires substantively the same core elements as Florida: a statement that the therapy is not FDA-approved, the anticipated results, the available alternatives, the material risks, and the option to decline. Utah’s structure pairs a posted notice with a written disclosure the patient signs and dates, retained in the medical record. The dated signature is worth flagging as a Utah-specific emphasis: build the date line into the form rather than treating it as optional. Verify the exact wording and the supplier-side mechanics against the consolidated current text of Section 58-1-512 as amended, because the section has been amended more than once and secondary summaries have not always been precise.
Wyoming SF 48 Consent Requirements
Wyoming’s SF 48 takes a different drafting approach. It requires that written informed consent be obtained and that a documented physician-patient relationship exist before therapy, but it does not enumerate the specific consent elements in the itemized way Florida and Utah do. That absence is not a license to use a thinner form. The defensible approach for a Wyoming physician is to treat the Florida and Utah enumerated elements as a floor, the FDA non-approval statement, anticipated results, alternatives, material risks, and the option to decline, and to confirm with Wyoming healthcare counsel whether general Wyoming informed-consent law or Board of Medicine rules add anything further. Building to the higher standard costs nothing and closes the gap that an under-specified statute leaves open.
Cross-State Consent Requirements Comparison
| Required element | Florida SB 1768 | Utah 58-1-512 | Wyoming SF 48 |
|---|---|---|---|
| FDA non-approval statement | Explicitly required | Explicitly required | Implied by written-consent duty; confirm with counsel |
| Anticipated results | Explicitly required | Explicitly required | Recommended floor; confirm with counsel |
| Alternative therapies | Explicitly required | Explicitly required | Recommended floor; confirm with counsel |
| Material risks | Explicitly required | Explicitly required | Recommended floor; confirm with counsel |
| Option to decline therapy | Explicitly required | Explicitly required | Recommended floor; confirm with counsel |
| Patient signature | Required | Required | Required |
| Date of signature | Recommended | Required | Recommended |
| Retained in medical record | Required | Required | Required under general records law |
| Physician signature | Recommended | Recommended | Recommended |
Elements Every Consent Form Should Include Regardless of State
Beyond the state-specific items, a robust form should also identify the specific procedure being performed, including the tissue type and administration method, and the name and credentials of the performing physician. It should explain in plain language what “not FDA-approved” actually means: not an approved drug, not reviewed for safety and efficacy for this or any condition through pre-market approval. Where the patient’s tissue is being banked, the form should state that separately and describe the conditions under which it may later be used. Finally, it should record that the patient had the opportunity to ask questions and that they were answered, along with the date and time of consent. These additions strengthen the file in any state and cost nothing to include.
Common Consent Documentation Failures and How to Avoid Them
The recurring failure modes are predictable. A generic surgical consent form with a handwritten stem cell addendum does not satisfy enumerated statutory elements; a dedicated form is required. Verbal consent documented only in a chart note fails a written-and-signed requirement outright. Using one combined form for both banking and therapy blurs two procedures with different risk profiles, so separate forms are the safer design. And filing a signed consent without a retention policy tied to the applicable state’s records rule leaves a gap that surfaces years later when the file is requested. Each of these is avoidable with a dedicated, state-reviewed form and a documented retention policy.
Consent Form Element Checklist
- FDA non-approval statement present and clearly worded.
- Anticipated results described factually, without guarantee language.
- Alternative therapies listed.
- Material risks described.
- Option of not receiving therapy stated.
- Patient signature line present.
- Date line present.
- Physician signature line present.
- Retention policy established and staff trained.
- Form reviewed by qualified healthcare counsel in the applicable state before use.
Frequently Asked Questions
Is a thorough verbal consent conversation enough if I document it in the chart?
No. Florida and Utah require specific elements in a signed written form retained in the record. A chart note describing a verbal conversation does not satisfy a written-form requirement, however complete the conversation was.
Can I use one consent form for both banking and therapy?
It is not recommended. Banking and therapy are distinct procedures with distinct risk profiles, and a combined form tends to under-describe the risks of each. Separate forms are the cleaner and more defensible design.
Wyoming SF 48 does not list consent elements. Does that mean a short form is fine?
No. The absence of enumerated elements is not a lower standard. Use the Florida and Utah elements as a floor and confirm with Wyoming counsel whether anything further applies under general state law or Board rules.
Key Takeaways
Across Florida, Utah, and Wyoming, the consent form has become a statutory compliance artifact, not just an ethics formality, and the safest single move a multi-state practice can make is to build one form to the highest common standard: the FDA non-approval statement, anticipated results, alternatives, material risks, and the option to decline, signed and dated, retained per the applicable records rule, and reviewed by counsel in each state of practice. Florida and Utah enumerate those elements; Wyoming requires written consent without itemizing, which means the enumerated elements function as a sensible floor there too. The failure modes are mundane and avoidable: generic forms, verbal-only consent, combined banking-and-therapy forms, and no retention policy. None of this concerns banking itself, which is a preservation decision separate from any therapy, but the consent discipline a practice builds for therapy is the same discipline that should govern how banking is documented.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Practices building or auditing a consent workflow can contact Save My Fat to discuss how tissue preservation is documented. Service and processing details are available at https://savemyfat.com/pricing/.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
